Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-β-lactamase inhibitor combination, against Escherichia coli

被引：14

作者：

Bantar, C

Nicola, F

Arenoso, HJ

Galas, M

Soria, L

Dana, D

Rossi, A

Bianchini, H

Jasovich, A

机构：

[1] Centro Educ Med & Invest Clin, Buenos Aires, DF, Argentina

[2] Lab Bago SA, Buenos Aires, DF, Argentina

[3] Inst Nacl Microbiol Carlos Malbran, Buenos Aires, DF, Argentina

[4] Hosp Privado Antartido, Buenos Aires, DF, Argentina

[5] Centro Farm Clin Aplicada, Buenos Aires, DF, Argentina

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 06期

关键词：

D O I：

10.1128/AAC.43.6.1503

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We evaluated the pharmacokinetics of amoxicillin-sulbactam (AMX-SUL), a novel drug combination, and its pharmacodynamics against Escherichia coli in 12 volunteers receiving a single oral dose (1,000 mg). Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (greater than or equal to 16-mg/liter) (47 strains), respectively.

引用

页码：1503 / 1504

页数：2

共 10 条

[1]

ARLET G, 1991, FEMS MICROBIOL LETT, V82, P19

[2] SYNERGY CHARACTERIZATION FOR ENTEROCOCCUS-FAECALIS STRAINS DISPLAYING MODERATELY HIGH-LEVEL GENTAMICIN AND STREPTOMYCIN RESISTANCE [J].